Danaher Subsidiary Cepheid Receives FDA Approval for Xpert Hemorrhagic Fever Panel
Cepheid, a subsidiary of Danaher (DHR), has received U.S. FDA approval for its Xpert Hemorrhagic Fever Panel. This PCR-based diagnostic test is designed to detect multiple hemorrhagic fever viruses simultaneously from a single patient sample, streamlining the diagnostic process for high-risk viral infections. The approval marks a significant expansion of Cepheid's molecular diagnostic portfolio. By enabling rapid detection of various hemorrhagic fevers through one test, the product aims to improve clinical response times and public health monitoring in regions affected by these viruses.
Tickers: $DHR
Topics: FDA approval hemorrhagic fever medical diagnostics PCR testing